Key clinical point: Serum calprotectin (CLP) serves as an important inflammatory biomarker for diagnosing and monitoring disease activity in psoriatic arthritis (PsA).
Major finding : Participants with PsA vs control individuals without psoriasis or PsA had higher median CLP levels (3.816 vs 0.707 μg/mL; P < .001). The concentration of serum CLP decreased significantly along with the disease activity from 3.816 at baseline to 2.052, 1.681, and 1.655 μg/mL at 3, 6, and 12 months, respectively (all P < .001).
Study details : Findings are from a longitudinal study including 71 patients with PsA, 55 patients with psoriasis, and 50 control individuals.
Disclosures: This study was supported by the interdisciplinary clinical research project of Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.
Source: Li B et al. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2022 (Oct 21). Doi: 10.1007/s40744-022-00501-5